Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Packer M,
Anker SD,
Butler J,
Filippatos G,
Pocock SJ,
Carson P,
Januzzi J,
Verma S,
Tsutsui H,
Brueckmann M,
Jamal W,
Kimura K,
Schnee J,
Zeller C,
Cotton D,
Bocchi E,
Böhm M,
Choi DJ,
Chopra V,
Chuquiure E,
Giannetti N,
Janssens S,
Zhang J,
Gonzalez Juanatey JR,
Kaul S,
Brunner-La Rocca HP,
Merkely B,
Nicholls SJ,
Perrone S,
Pina I,
Ponikowski P,
Sattar N,
Senni M,
Seronde MF,
Spinar J,
Squire I,
Taddei S,
Wanner C,
Zannad F
N Engl J Med 2020;383:1413–24 DOI 10.1056/NEJMoa2022190
SGLT-2 inhibitors – such as empagliflozin – may slow progression of cardiac and renal disease. In this randomised, double-blind, parallel-group, placebo-controlled study, 3,730 patients with chronic HF and a greater severity of LVSD were randomised 1:1 to empagliflozin 10 mg or placebo, with outcomes and AEs evaluated every 2–3 months. CV outcomes were improved with empagliflozin versus placebo, and this was consistent across prespecified subgroups. Safety concerns with other drugs for HF were not seen with empagliflozin in this study.